Clinical trials: Glucagon
Obesity, Normal Weight
Hormonal Control of Energy and Macronutrient Intake in Obesity (MEMORY)
The overall aim of the MEMORY study is to examine the concept of 'food memory' - how specific macronutrient compositions influence subsequent food preference and intake, and whether this differs across the BMI range from normal…
- Conditions
- Obesity, Normal Weight, Overweight
- Trial name
- MEMORY (NCT06752967)
- Testing
- High protein liquid test meal, High carbohydrate liquid test meal
- Where
- Denmark
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Obesity Morbid, Multimorbidity
Semaglutide and Physical Activity for Obesity and Multimorbidity
The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients…
- Conditions
- Obesity Morbid, Multimorbidity, Obesity
- Trial name
- NCT06234111
- Testing
- Semaglutide 2.4 mg, total diet replacement, behavioural intervention
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes Mellitus in Obese
Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
The very-low calorie diet (VLCD) is a highly effective and safe way to rapidly lose significant amounts of weight and dramatically improve blood sugar control in a short period of time (typically 8-12 weeks).
- Trial name
- SemVLCD (NCT05606471)
- Testing
- Semaglutide Pen Injector [Ozempic], Very-low Calorie Diet
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- University of Nottingham
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 1 Diabetes
Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes
Current intensive insulin therapy in T1D involves prandial insulin boluses depending on the carbohydrate content of each ingested meal.
- Trial name
- NCT02490098
- Testing
- 6-day intervention with sensor-augmented pump therapy, 6-day intervention with single-hormone closed-loop strategy, 6-day intervention with dual-hormone closed-loop strategy
- Where
- Canada
- Sponsor
- Institut de Recherches Cliniques de Montreal
Delayed Gastric Emptying, Gastroparesis
Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.
Given the increased prescription of GLP-1 agonists for both diabetes and obesity management and the implications of the proposed delayed gastric emptying in the setting of an anesthetic, it is critical to determine if patients…
- Trial name
- NCT06038734
- Testing
- gastric ultrasound
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Right Coronary Artery Percutaneous Coronary Intervention, Right Ventricular Diastolic Dysfunction
Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting
The heart requires nutrients and oxygen carried in the blood to generate energy for healthy pump function. Blood is supplied via heart vessels called coronary arteries.
- Trial name
- DREAM GLP-1 (NCT02236299)
- Testing
- Right Coronary Artery Percutaneous Coronary Intervention, GLP-1 Infusion
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Dose-response Study of Exendin-9,39 on Glucose Metabolism
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min.
- Trial name
- NCT01218633
- Testing
- saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Type 2 Diabetes
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes…
- Trial name
- NCT06481085
- Testing
- HDM1002 50 mg, HDM1002 100 mg, HDM1002 200 mg
- Where
- 31 sites in China
- Volunteers
- 324 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Liver Transplantation
Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion
The aim of the study is to investigate the significance of intact nerve supply to the liver for the glucagon-like peptide-1 (GLP-1) induced insulin secretion.
- Trial name
- NCT01176708
- Testing
- dipeptidyl peptidase 4 (DPP4) inhibitor, oral glucose, intravenous glucose
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes, Glucose Tolerance Impaired
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose…
- Conditions
- Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
- Trial name
- NCT05093517
- Testing
- REMD-477
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter, treat-to-target study of 26 weeks treatment duration will evaluate the efficacy and safety of once-weekly albiglutide versus placebo as…
- Trial name
- NCT02229240
- Testing
- Albiglutide
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, Steroids
Incretin Physiology Associated With Steroid Hormone Treatment
The purpose of this study is to evaluate whether the reduced incretin effect and the paradoxical glucagon responses during oral glucose ingestion and isoglycaemic iv glucose infusion observed in patients with type 2 diabetes are…
- Trial name
- NCT00713440
- Testing
- Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type2diabetes
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations.
- Trial name
- NCT05499702
- Testing
- Caloric Restriction, Hyperglycemic clamp
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Adrian Vella
Type 2 Diabetes Mellitus
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
Primary Objectives: To assess in overweight to obese T2DM patients: The glucagon receptor occupancy of SAR425899 at two dose levels in the human liver with positron-emission tomography (PET) imaging using…
- Trial name
- NCT03350191
- Testing
- SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Sanofi
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Diabetes Mellitus, Type 2
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
Mortality due to cardiovascular problems is increased by having Diabetes Mellitus type 2 (DM2), related to the time of evolution and glucose levels or if alterations in blood pressure coexist.
- Trial name
- NCT03444142
- Testing
- Exenatide LAR, Dulaglutide
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Diabetes, HIV Infections
The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism
The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients.
- Conditions
- Diabetes, HIV Infections, Insulin Resistance
- Trial name
- NCT00259727
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Dyslipidemia
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2
1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study A) 2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)
- Trial name
- NCT01958775
- Testing
- GLP-2
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
- Trial name
- MAINTAIN (NCT06734312)
- Testing
- Gastric Fundal Mucosal Ablation (GFMA)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dr. Christopher McGowan